Grünenthal announces acquisition of the rights to Cialis® from Lilly in Mexico, Brazil & Colombia

"Executing on our strategy of targeted acquisitions, Cialis® will expand our existing portfolio in the region and strengthen Grünenthal's Latin American business", says Gabriel Baertschi, CEO, Grünenthal. "In 2022, we acquired Nebido®, a long-acting treatment for testosterone deficiency, and with Cialis® we can continue to serve our existing customer base and foster our growth in key Latin American markets." "Executing on our strategy of targeted acquisitions, Cialis ®will expand our existing...

"Executing on our strategy of targeted acquisitions, Cialis^® will expand our existing portfolio in the region and strengthen Grünenthal's Latin American business", says Gabriel Baertschi, CEO, Grünenthal. "In 2022, we acquired Nebido^®, a long-acting treatment for testosterone deficiency, and with Cialis^® we can continue to serve our existing customer base and foster our growth in key Latin American markets."

Through the acquisition of Cialis^®, Grünenthal continues executing its strategy of acquiring established medicines to expand its portfolio and increase its profitability.  Since 2017, Grünenthal has invested over €2 billion in the acquisition of established medicines, including Nebido^®, the European rights to Crestor^® and Nexium^®, as well as the global rights to Vimovo^® (excluding the U.S. and Japan), Qutenza^® and Zomig^® (excluding Japan).  In 2023, Grünenthal established Grünenthal Meds, a joint venture with Kyowa Kirin International, which manages a portfolio of 13 brands primarily focused on pain management and, in 2024, acquired the US company Valinor Pharma and the product Movantik^®.

About Grünenthal

Grünenthal is a global leader in pain management and related diseases. As a science-based, fully integrated pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better – and innovation is our passion. We focus all our activities and efforts on working towards our vision of a World Free of Pain.

Grünenthal is headquartered in Aachen, Germany, and has affiliates in 28 countries across Europe, Latin America, and the U.S. Our products are available in approx. 100 countries. In 2024, Grünenthal employed around 4,300 people and achieved revenues of €1.8 billion.

More information: www.grunenthal.com 

Follow us on:

LinkedIn: Grunenthal Group
Instagram: grunenthal

For further information, please contact:

Maren Thurow
Head Global Communication

Grünenthal GmbH
52099 Aachen

E-Mail: [email protected]
Phone: +44 7917 196855

[1] In Mexico Cialis^® is indicated for the oral treatment of erectile dysfunction and symptoms of benign prostatic hyperplasia in adult men.

 

View original content:https://www.prnewswire.co.uk/news-releases/grunenthal-announces-acquisition-of-the-rights-to-cialis-from-lilly-in-mexico-brazil--colombia-302470601.html